Cargando…
Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice
BACKGROUND: Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM: To elucidate whether clopidogrel is beneficial against DN by using a db/db mouse model. METHODS: db/db mice wi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412856/ https://www.ncbi.nlm.nih.gov/pubmed/36159226 http://dx.doi.org/10.4239/wjd.v13.i8.600 |
_version_ | 1784775595420286976 |
---|---|
author | Li, Hong-Qin Liu, Nian Zheng, Zong-Yu Teng, Hao-Lin Pei, Jin |
author_facet | Li, Hong-Qin Liu, Nian Zheng, Zong-Yu Teng, Hao-Lin Pei, Jin |
author_sort | Li, Hong-Qin |
collection | PubMed |
description | BACKGROUND: Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM: To elucidate whether clopidogrel is beneficial against DN by using a db/db mouse model. METHODS: db/db mice with a higher urinary albumin/creatinine ratio (ACR) relative to age- and sex-matched wild-type control mice were randomly allocated to clopidogrel and vehicle treatment groups. Clopidogrel was administered at doses of 5, 10, and 20 mg/kg by gavage for 12 wk. Body mass, blood glucose level, and urinary creatinine and albumin concentrations in each group were measured before and after the intervention. Renal fibrosis was evaluated using periodic acid-Schiff and Masson’s trichrome staining. The renal protein expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and F4/80 was assessed using immunohistochemistry. Urinary TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-6 levels were analyzed using enzyme-linked immunosorbent assay; TNF-α and IL-1β mRNA expression was measured using real-time quantitative polymerase chain reaction. The protein expression of fibronectin (FN) and collagen I was assessed using immunohistochemistry. RESULTS: Clopidogrel treatment did not affect the body mass or blood glucose level of the db/db mice; however, it increased bleeding time and reduced urinary ACR in a dose-dependent manner. Immunohistochemical staining revealed an amelioration of renal fibrosis, significantly lower deposition of FN and collagen I, and significantly lower expression of the proinflammatory cytokines TNF-α and IL-1β and lower levels of urinary TNF-α and MCP-1 in the clopidogrel-treated db/db mice (P < 0.05). Furthermore, clopidogrel significantly reduced macrophage infiltration into the glomeruli of the db/db mice. CONCLUSION: Clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db/db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. |
format | Online Article Text |
id | pubmed-9412856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-94128562022-09-23 Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice Li, Hong-Qin Liu, Nian Zheng, Zong-Yu Teng, Hao-Lin Pei, Jin World J Diabetes Basic Study BACKGROUND: Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM: To elucidate whether clopidogrel is beneficial against DN by using a db/db mouse model. METHODS: db/db mice with a higher urinary albumin/creatinine ratio (ACR) relative to age- and sex-matched wild-type control mice were randomly allocated to clopidogrel and vehicle treatment groups. Clopidogrel was administered at doses of 5, 10, and 20 mg/kg by gavage for 12 wk. Body mass, blood glucose level, and urinary creatinine and albumin concentrations in each group were measured before and after the intervention. Renal fibrosis was evaluated using periodic acid-Schiff and Masson’s trichrome staining. The renal protein expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and F4/80 was assessed using immunohistochemistry. Urinary TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-6 levels were analyzed using enzyme-linked immunosorbent assay; TNF-α and IL-1β mRNA expression was measured using real-time quantitative polymerase chain reaction. The protein expression of fibronectin (FN) and collagen I was assessed using immunohistochemistry. RESULTS: Clopidogrel treatment did not affect the body mass or blood glucose level of the db/db mice; however, it increased bleeding time and reduced urinary ACR in a dose-dependent manner. Immunohistochemical staining revealed an amelioration of renal fibrosis, significantly lower deposition of FN and collagen I, and significantly lower expression of the proinflammatory cytokines TNF-α and IL-1β and lower levels of urinary TNF-α and MCP-1 in the clopidogrel-treated db/db mice (P < 0.05). Furthermore, clopidogrel significantly reduced macrophage infiltration into the glomeruli of the db/db mice. CONCLUSION: Clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db/db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Baishideng Publishing Group Inc 2022-08-15 2022-08-15 /pmc/articles/PMC9412856/ /pubmed/36159226 http://dx.doi.org/10.4239/wjd.v13.i8.600 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Li, Hong-Qin Liu, Nian Zheng, Zong-Yu Teng, Hao-Lin Pei, Jin Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title | Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title_full | Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title_fullStr | Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title_full_unstemmed | Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title_short | Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
title_sort | clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412856/ https://www.ncbi.nlm.nih.gov/pubmed/36159226 http://dx.doi.org/10.4239/wjd.v13.i8.600 |
work_keys_str_mv | AT lihongqin clopidogreldelaysandcanreversediabeticnephropathypathogenesisintype2diabeticdbdbmice AT liunian clopidogreldelaysandcanreversediabeticnephropathypathogenesisintype2diabeticdbdbmice AT zhengzongyu clopidogreldelaysandcanreversediabeticnephropathypathogenesisintype2diabeticdbdbmice AT tenghaolin clopidogreldelaysandcanreversediabeticnephropathypathogenesisintype2diabeticdbdbmice AT peijin clopidogreldelaysandcanreversediabeticnephropathypathogenesisintype2diabeticdbdbmice |